ARTICLE | Clinical News
Pimavanserin tartrate: Phase III started
August 2, 2010 7:00 AM UTC
Acadia began the double-blind, placebo-controlled, North American Phase III (020) trial to evaluate 40 mg oral pimavanserin for 6 weeks as adjunct to dopamine replacement therapy in 200 patients. Acad...